288 related articles for article (PubMed ID: 26720415)
41. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
[TBL] [Abstract][Full Text] [Related]
42. Intracranial Injection of Dengue Virus Induces Interferon Stimulated Genes and CD8+ T Cell Infiltration by Sphingosine Kinase 1 Independent Pathways.
Al-Shujairi WH; Clarke JN; Davies LT; Alsharifi M; Pitson SM; Carr JM
PLoS One; 2017; 12(1):e0169814. PubMed ID: 28095439
[TBL] [Abstract][Full Text] [Related]
43. Immunogenicity of a Candidate DNA Vaccine Based on the prM/E Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain.
Putri DH; Sudiro TM; Yunita R; Jaya UA; Dewi BE; Sjatha F; Konishi E; Hotta H; Sudarmono P
Jpn J Infect Dis; 2015; 68(5):357-63. PubMed ID: 25766602
[TBL] [Abstract][Full Text] [Related]
44. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
[TBL] [Abstract][Full Text] [Related]
45. A Combined Genetic-Proteomic Approach Identifies Residues within Dengue Virus NS4B Critical for Interaction with NS3 and Viral Replication.
Chatel-Chaix L; Fischl W; Scaturro P; Cortese M; Kallis S; Bartenschlager M; Fischer B; Bartenschlager R
J Virol; 2015 Jul; 89(14):7170-86. PubMed ID: 25926641
[TBL] [Abstract][Full Text] [Related]
46. SUMO Modification Stabilizes Dengue Virus Nonstructural Protein 5 To Support Virus Replication.
Su CI; Tseng CH; Yu CY; Lai MMC
J Virol; 2016 May; 90(9):4308-4319. PubMed ID: 26889037
[TBL] [Abstract][Full Text] [Related]
47. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
48. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
[TBL] [Abstract][Full Text] [Related]
50. Viperin is anti-viral
Al Shujairi WH; Kris LP; van der Hoek K; Cowell E; Bracho-Granado G; Woodgate T; Beard MR; Carr JM
J Gen Virol; 2021 Oct; 102(10):. PubMed ID: 34665110
[TBL] [Abstract][Full Text] [Related]
51. Mouse models of dengue virus infection for vaccine testing.
Sarathy VV; Milligan GN; Bourne N; Barrett AD
Vaccine; 2015 Dec; 33(50):7051-60. PubMed ID: 26478201
[TBL] [Abstract][Full Text] [Related]
52. Dengue virus is sensitive to inhibition prior to productive replication.
Talemi SR; Bartenschlager M; Schmid B; Ruggieri A; Bartenschlager R; Höfer T
Cell Rep; 2021 Oct; 37(2):109801. PubMed ID: 34644578
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
[TBL] [Abstract][Full Text] [Related]
54. Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models.
Tang WW; Grewal R; Shresta S
Curr Opin Virol; 2015 Aug; 13():61-6. PubMed ID: 26001278
[TBL] [Abstract][Full Text] [Related]
55. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
56. Narasin, a novel antiviral compound that blocks dengue virus protein expression.
Low JS; Wu KX; Chen KC; Ng MM; Chu JJ
Antivir Ther; 2011; 16(8):1203-18. PubMed ID: 22155902
[TBL] [Abstract][Full Text] [Related]
57. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
[TBL] [Abstract][Full Text] [Related]
58. Innate Antiviral Immunity against Dengue Virus.
Makhluf H; Shresta S
Crit Rev Immunol; 2015; 35(3):253-60. PubMed ID: 26559229
[TBL] [Abstract][Full Text] [Related]
59. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris.
Tang YX; Jiang LF; Zhou JM; Yin Y; Yang XM; Liu WQ; Fang DY
Chin Med J (Engl); 2012 Jun; 125(11):1986-92. PubMed ID: 22884066
[TBL] [Abstract][Full Text] [Related]
60. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
